Biotech Showcase™ 2020: Promise for patients and families living with rare neurological disorders

https://informaconnect.com/biotech-sh... Speaking at Biotech Showcase 2020, Dr. Jeremy Levin, Chairman and CEO, Ovid Therapeutics, updates Erik Clausen on the biopharmaceutical company's progress with its investigational medicine, OV101 (gaboxadol) for the treatment of Angelman syndrome and Fragile X syndrome. Levin also discusses progress with OV935 (soticlestat) being developed for the potential treatment of rare developmental and epileptic encephalopathies (DEE) as well as his thoughts on biotech investment in 2020.